EPISODE #146 Overview of European Cannabis with Antonio Costanzo, Chief Executive Officer at Curaleaf International
The Cannabis Conversation | Medical Cannabis | CBD | Hemp01/10/22 • 41 min
In our latest episode, we’re joined by Antonio Costanzo - CEO of Curaleaf International. Curaleaf is a leading US multi-state operator, and Curaleaf International is Europe’s largest vertically integrated cannabis company.
We examine the developing demand for medical and recreational cannabis use across Europe, looking into the various referendums, pilot projects, and regulatory changes underpinning the liberalisation of cannabis across the continent.
📚 VIEW SHOW NOTES AND EXTRAS:
https://www.canverse.global/shownotes/e146
I’m really pleased to announce our new show sponsor - Lumino!
Lumino is a boutique HR Agency that specialises in building high performance teams for the European cannabis industry - working in three main verticals: Commercial, Medical and Plant Facing
About Antonio Costanzo - Chief Executive Officer, Curaleaf International
Antonio Costanzo is an experienced senior executive with a successful track record in public and private companies and in innovative, complex and highly regulated industries. Before co-founding EMMAC, now Curaleaf International, he was instrumental in the successful development of Nuuvera, a Canadian publicly listed cannabis company that was acquired by Aphria, in March 2018. He led the company’s development in Europe, Africa and South America.
Prior to focusing on the cannabis industry, he was Head of Public Policy and Government Relations at Uber in the key European markets. He formerly spent 10 years in the online gaming industry, at bwin, as Director of International Development and Regulatory Affairs, developing the group’s activities across Europe.
He served for 5 years as vice-Chairman and board Director at ESSA – Sport Betting Integrity. He started his career in the media industry, at Eurosport, where he launched and managed the Italian market. Fluent in 4 languages, he has developed an extensive political and business network across Europe.
Quotables
“But clearly cannabis shouldn't be treated as aspirin or as paracetamol. You know, it has some peculiarities that need to be taken into account and addressed. And I think that this is a challenge that we have as an industry is supporting regulators in identifying the ways that can make medical cannabis more accessible to patients.”
“Those of us who will be here in 10, 15, 20 years, we see this industry evolve dramatically in a way that is difficult to predict today. But clearly it's going to be one of the big worldwide industries that will shape the economy in the coming 10,15, 20 years.”
Resources
Curaleaf International’s Website: https://curaleaf.com/
Follow Antonio on LinkedIn: https://www.linkedin.com/in/antoniocostanzo/?originalSubdomain=uk
Follow Curaleaf on LinkedIn: https://www.linkedin.com/company/curaleaf
01/10/22 • 41 min
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/the-cannabis-conversation-medical-cannabis-cbd-hemp-237547/episode-146-overview-of-european-cannabis-with-antonio-costanzo-chief-26467450"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode #146 overview of european cannabis with antonio costanzo, chief executive officer at curaleaf international on goodpods" style="width: 225px" /> </a>
Copy